Where We Stand On Pharmaceutical Patent Settlements
Two and a half years after the pivotal U.S. Supreme Court opinion in Federal Trade Commission v. Actavis Inc.,[1] lower courts continue to grapple with the broad contours of that decision....To view the full article, register now.
Already a subscriber? Click here to view full article